Biological medicines - generic substitution, pharmaceutical markets, and prescription guidelines
Published 1.1.2024
This register research project studies the effects of the generic substitution of biological medicines on the use, costs, and reimbursement costs of health insurance. It also examines the life cycle, competition and market situation, and availability of biological medicines after the introduction of the generic substitution of biological medicines. In addition, the guidance for and supervision of the prescription of biological medicines will be studied.
The project is part of a consortium study whose main responsible parties are Kela, the Department of Pharmacy at the University of Eastern Finland and the Department of Pharmacy at the University of Helsinki.
Researchers
- Kati Sarnola, Principal Investigator
- Hanna Koskinen
- Klaudia Kaustiala
- Pekka Heino
- Heini Kari
- Hanna Rättö
- Terhi Kurko
- Markus Kainu
- Monika Fuss
- Iiro Ahomäki
Duration of the project
1.1.2024–31.12.2028
Project results
- Treatment costs of novel medicines and the relative importance of biologic status to treatment costs – Retrospective register study in Finland in 2011–2021 (FIP World Congress of Pharmacy and Pharmaceutical Sciences 1.-4.9.2024)
- Have medication safety alerts reflected on the use of JAK inhibitors? – Retrospective nationwide register-based study in 2017–2023 (FIP World Congress of Pharmacy and Pharmaceutical Sciences 1.-4.9.2024)
- How has biosimilar prescribing evolved? Register study on the changes in prescribing in 2018–2023 (FIP World Congress of Pharmacy and Pharmaceutical Sciences 1.-4.9.2024)
- Finland as a trailblazer in the uptake of less expensive biologic medicines (FIP World Congress of Pharmacy and Pharmaceutical Sciences 1.-4.9.2024)
